Percutaneous Myocardial Laser Developer Drafts IDE Agreement With FDA
This article was originally published in The Gray Sheet
Executive Summary
CardioGenesis will meet with FDA by year-end to finalize a clinical trial protocol to support PMA approval of its Axcis laser percutaneous myocardial channeling (PMC) system for treating severe angina
You may also be interested in...
Cardiogenesis trials
Foothill Ranch, Calif.-based company submits IDE application to FDA to conduct trials supporting angina treatment indication for percutaneous myocardial channeling (PMC) system, the firm announces July 6. Cardiogenesis secured an agreement from FDA in June on key aspects of the trial design, endpoints and patient criteria for the study protocol. The company plans to leverage data from an Axcis PMC device rejected by FDA in 2001 (1"The Gray Sheet" Nov. 22, 2004, p. 14)...
Cardiogenesis trials
Foothill Ranch, Calif.-based company submits IDE application to FDA to conduct trials supporting angina treatment indication for percutaneous myocardial channeling (PMC) system, the firm announces July 6. Cardiogenesis secured an agreement from FDA in June on key aspects of the trial design, endpoints and patient criteria for the study protocol. The company plans to leverage data from an Axcis PMC device rejected by FDA in 2001 (1"The Gray Sheet" Nov. 22, 2004, p. 14)...
CardioGenesis Prepares For New Trial Of Percutaneous Laser Angina Device
CardioGenesis credits the recent regulatory progress of its Axcis laser percutaneous myocardial channeling (PMC) system to the contributions of Syncardia CEO Marvin Slepian, MD